書籍詳細

I. 基礎編

P.12 掲載の参考文献

• 1) MacDonald HR:Development and selection of NKT cells. Curr Opin Immunol 14:250-254, 2002.
  pubmed

• 2) Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S:Functions of natural killer cells. Nat Immunol 9:503-510, 2008.
  pubmed

• 3) Lanier LL:Up on the tightrope:natural killer cell activation and inhibition. Nat Immunol 9:495-502, 2008.
  pubmed

• 4) Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO:Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4:77-85, 1996.
  pubmed

• 5) Lanier LL:NK cell receptors. Annu Rev Immunol 16:359-393, 1998.
  pubmed

• 6) Vyas YM, Mehta KM, Morgan M, Maniar H, Butros L, Jung S, Burkhardt JK, Dupont B:Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J Immunol 15; 167:4358-4367, 2001.

• 7) Shibuya A, Campbell D, Hamum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH:DNAM-1. a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4:573-581, 1996.

• 8) Gumperz JE, Miyake S, Yamamura T, Brenner MB:Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 4; 195:625-636, 2002.

• 9) Fujii S, Shimizu K, Kronenberg M, Steinman RM:Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3:867-874, 2002.
  pubmed

• 10) Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M:CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 28; 278:1626-1629, 1997.

• 11) Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, Franck RW, Tsuji M, Steinman RM:Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA 25; 103:11252-11257, 2006.

P.17 掲載の参考文献

• 1) Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ:Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 15; 100:3835-3837, 2002.

• 2) Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M:Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 116:601 603, 2002.

• 3) Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H:Identification of a WT1 protein-derived peptide. WT1. as a HLA-A 0206-restricted. WT1-specific CTL epitope. Microbiol Immunol 52:551-558, 2008.
  pubmed

• 4) Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T. Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K:Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19:804-814, 2006.

• 5) Oji Y, Inohara H, Nakazawa M, Nakano Y, Akahani S, akatsuka S, Koga S, Ikeba A, Abeno S, Honjo Y, Yamamoto Y, Iwai S, Yoshida K, Oka Y, Ogawa H, Yoshida J, Aozasa Kubo T, Sugiyama H:Overexpression of the Wilms'tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94:523-529, 2003.

• 6) Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H:WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211-220, 2008.
  pubmed

• 7) Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ:Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1; 151:3693-3703, 1993.
  pubmed

• 8) Abe H, Akiyama S, and Okamoto M:Clinical Cancer Immunotherapy:Molecular Targeting Immunotherapy. Intemational Journal of Integrative Medicine 1 (1):38-46, 2009.

P.19 掲載の参考文献

• 1) Murshid A, Gong J, Calderwood SK:Heat-shock proteins in cancer vaccines:agents of antigen cross-presentation. Expert Rev Vaccines 7 (7):1019-1030, 2008.
  pubmed

• 2) Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C:Toll-like receptor 3 promotes cross-priming to virus-infected cell. Nature 24; 433:887-892, 2005.

P.22 掲載の参考文献

• 1) Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T:A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 13; 254:1643-1647, 1991.

• 2) Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM:The prioritization of cancer antigens:a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 1; 15:5323-5337, 2009.

II. 臨床編

P.27 掲載の参考文献

• 1) KS Akagawa, N Takasuka, Y Nozaki, I Komuro, M Azuma, M Ueda, M Naito and K Takahashi:Human monocytes phosphatase-positive osteoclast-like multinucleated giant cells from Generation of CD1+RelB+dendritic cells and tartrate-resistant acid. Blood 88:4029-4039, 1996.

• 2) Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den DP, Knop J, Brocker EB, Enk A, Kampgen E, Schuler G:Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165:3492-3496, 2000.

• 3) Schuler-Thurner B, Schultz ES, Berger T, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G:Rapid induction of tumor-specific type 1 helper T cells in metastatic melanoma patients by vaccination with mature. cryopreserved. peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288, 2002.
  pubmed

• 4) David W, O'Neill, Sylvia Adams and Nina Bhardwaj:Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235-2246, 2004.

P.31 掲載の参考文献

• 1) 阿部博幸, 秋山真一郎, 岡本正人:臨床におけるがん免疫療法-分子標的免疫療法の実際. Int J Integrative Med 1 (1):38-46, 2009.

P.35 掲載の参考文献

• 1) Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM:Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma:assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58:1-14, 2009.
  pubmed

• 2) Figdor CG, de Vries IJ, Lesterhuis WJ:Melief CJ.:Dendritic cell immunotherapy:mapping the way. Nat Med 10 (5):475-480, 2004.
  pubmed

• 3) Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E:Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171:6275-6282, 2003.
  pubmed

• 4) Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M:Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res l; 64:5461-5470, 2004.

P.36 掲載の参考文献

• 1) Chen T, Cao X:Stress for maintaining memory:HSP70 as a mobile messenger for innate and adaptive immunity. Eur J Immunol 40 (6):1541-1544, 2010.
  pubmed

P.38 掲載の参考文献

• 1) 山岡昇, 岡三喜男:化学療法薬物有害反応の対策. 臨床腫瘍学, 第3版, 日本臨床腫瘍学会編, pp1136-1150, 癌と化学療法社, 東京, 2003.

• 2) Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F:Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18:1332-1339, 2004.
  pubmed

• 3) Balabanov S, Appel S, Kanz L, Brossart P, Brummendorf TH:Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. Ann NY Acad Sci 1044:168-177, 2005.
  pubmed

• 4) Larmonier N, Janikashvili N, LaCasse CJ, Larrnonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E:Imatinib mesylate inhibits CD4+CD25+regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol 181:6955-6963, 2008.

• 5) Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D, Isnardon D, Olive D, Gaugler B:Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 103:4666-4668, 2004.
  pubmed

• 6) Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Arrnitage JO, Balducci L, Bennett CL, Cantor SB, rawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC:2006 update of recommendations for the use of white blood cell growth factors:an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006.

P.44 掲載の参考文献

• 1) http://www.jcog.jp/doctor/tool/recistv11.html

• 2) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
  pubmed

P.51 掲載の参考文献

• 1) Hanahan D, Weinberg RA:The hallmarks of cancer. Cell 100:57-70, 2000.
  pubmed

• 2) Stephanie Gout, Jacques Huot:Role of Cancer Microenvironment in Metastasis:Focus on Colon Cancer. Cancer Microenvironment 1:69-83, 2008.
  pubmed

• 3) Banchereau J, Steinman RM:Dendritic cells and the control of immunity. Nature 392:245-252, 1998.
  pubmed

• 4) Mellman I, Steinman RM:Dendritic cells:specialized and regulated antigen processing machines. Cell 106:255-258, 2001.
  pubmed

• 5) Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A, Banchereau J:CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α:II. Functional analysis. Blood 90:1458-1470, 1997.

• 6) Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J:Plasma-cytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-234, 2003.

• 7) Femandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L:Dendritic cells directly trigger NK cell functions:cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med 5:405-411, 1999.

• 8) Kadowaki N, Antonenko S, Ho S, Rissoan MC, Soumelis V, Porcelli SA, Lanier LL, Liu YJ:Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J Exp Med 193:1221-1226, 2001.
  pubmed

• 9) Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ:Dendritic cell immunotherapy:mapping the way. Nat Med 10:475-480, 2004.
  pubmed

• 10) Turtle CJ, Hart DN:Dendritic cells in tumor immunology and immunotherapy. Curr Drug Targets 5:17-39, 2004.
  pubmed

• 11) Engleman EG:Dendritic cell-based cancer immunotherapy. Semin Oncol 30:23-29, 2003.
  pubmed

• 12) Chang DH, Dhodapkar MV:Dendritic cells and immunotherapy for cancer. Int J Hematol 77:439-443, 2003.
  pubmed

• 13) Schuler G, Schuler-Thurner B, Steinman RM:The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147, 2003.
  pubmed

• 14) O'Neill DW, Adams S, Bhardwaj N:Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235-2246, 2004.
  pubmed

• 15) Conrad C, Nestle FO:Dendritic cell-based cancer therapy. Curr Opin Mol Ther 5:405-412, 2003.
  pubmed

• 16) Nestle FO, Banchereau J, Hart D:Dendritic cells:On the move from bench to bedside. Nat Med 7:761-765, 2001.
  pubmed

• 17) Ridgway D:The first 1000 dendritic cell vaccinees. Cancer Invest 21:873-886, 2003.
  pubmed

• 18) Romero P, Cerottini JC, Speiser DE:Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 53:249-255, 2004.
  pubmed

• 19) Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M:Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly (lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 287:109-124, 2004.
  pubmed

• 20) Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG:New guidelines to evaluate the response to treatment in solid tumours:European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000.

• 21) Floyd E, McShane TM:Development and use of biomarkers in oncology drug development. Toxicol Pathol 32 (Suppl 1):106-115, 2004.

• 22) Kawasaki H:Potential of application for cancer gene diagnosis using circulating nucleic acids (Free DNA) and Peripheral Blood Mononuclear Cells (PBMCs). Int J Integrative Med 2 (1):43-51, 2010.

• 23) 秋山真一郎, 阿部博幸:癌関連遺伝子マーカーによる分子標的免疫細胞療法の治療効果判定に関する研究. Int J Integrative Med 2 (1):141-146, 2010.

• 24) Kawasaki H, Akiyama S, Hamaya K, Abe H:DNA methylation and cancer. Int J Integrative Med 3 (1):36-45, 2011.

• 25) Muller HM, Widschwendter A, Fiegl H, Ivarson L, Goekel G, Perkmann E, Marth C, Widschwendter M:Cancer Res 63:764?-7645, 2003.

• 26) Kawasaki H, Akiyama S, Hamaya K, Abe H:DNA aberrant methylation in cancer:Its role and function. 11th International Congress of integrative Medicine, July 17-18, 2010 Tokyo, Japan.

P.60 掲載の参考文献

• 1) William B. Coley:A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. Post-graduate 8:278-286, 1893.

• 2) Wiemann B, Starnes CO:Coley's toxins. tumor necrosis factor and cancer research:a historical perspective. Pharmacol Ther 64:529-564, 1994.

• 3) Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al:Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 5; 313:1485-1492, 1985.

• 4) Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM:A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702-3709, 2002.

• 5) Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T:Autologous natural killer cell therapy for human recurrent malignant glioma.. Anticancer Res 24 (3b):1861-1871, 2004.
  pubmed

• 6) Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G:Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells:a clinical phase I trial. Clin Cancer Res 1; 10 (11):3699-3707, 2004.
  pubmed

• 7) Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA:Aphase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 59 (12):1781-1789, 2010.

• 8) Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T:A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12:6079-6086, 2006.

• 9) Motohashi S, Nakayama T:Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 99:638-645, 2008.
  pubmed

• 10) Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T:A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.. Clin Cancer Res 11:1910-1917, 2005.
  pubmed

• 11) Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ:Therapeutic activation of Valpha24+Vbeta11+NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383-389, 2004.
  pubmed

• 12) Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV:Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503-1517, 2005.
  pubmed

• 13) Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, Waterfall M, Samuel K, Yin J, Johnson P, Tumer M:Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol 133:152-157, 2006.

• 14) Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R:Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma:clinical and immune responses in 35 patients. Blood 99:1517-1526, 2002.
  pubmed

• 15) Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM:Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma:assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58:1-14, 2009.
  pubmed

• 16) Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M:Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7 (8):2277-2284, 2001.
  pubmed

• 17) Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, Kawano K, Kitano S:A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52:155-161, 2003.
  pubmed

• 18) Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E:Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171:6275-6282, 2003.
  pubmed

• 19) MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F:Regulation of dendritic cell migration to the draining lymph node:impact on T lymphocyte traffic and priming. J Exp Med 198:615-621, 2003.

• 20) Wilczynski JR, Duechler M:How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Exp (Warsz) 58 (6):435-448, 2010.
  pubmed

• 21) Kerbel RS, Kamen BA:The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004.
  pubmed

• 22) Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F:CD4+CD25+regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344, 2004.
  pubmed

• 23) Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, Tsuchiya T, Ueda Y, Inoue H, Hotta T, Kato S:Enhancement of human cord blood CD34+cell-derived NK cell cytotoxicity by dendritic cells.. J Immunol 166:1590-1600, 2001.
  pubmed

• 24) Piccioli D, Sbrana S, Melandri E, Valiante NM:Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195:335-341, 2002.
  pubmed

• 25) Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G:Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195:327-333, 2002.
  pubmed

• 26) Femandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L:Dendritic cells directly trigger NK cell functions:cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5:405-411, 1999.

P.82 掲載の参考文献

• 2) Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, Kawano K, Kitano S:A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52:155-161, 2003.
  pubmed

• 3) 秋山真一郎, 阿部博幸:原発性肝臓癌に対し, ハイブリッド免疫療法と高濃度ビタミンC点滴療法が奏効した一例. Int J Integrative Med 3 (1):143-151, 2011.

• 4) Akiyama S, Okamoto M, Tomoda T, Abe H:Clinical responses in patients with gastroenterological cancer treated with dendritic cell-based cancer vaccine. Preliminary report from multi-institutional retrospective analysis. BIT's 3rd World Cancer Congress 2010, Singapore, June 24, 2010 Singapore.

P.89 掲載の参考文献

• 1) Gisselsson D, Pettersson L, Hoglund M, Heidenblad M, Gorunova L, Wiegant J, Mertens F, Dal Cin P, Mitelman F, Mandahl N:Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci USA 97:5357-5362, 2000.
  pubmed

• 2) Van Heek NT, Meeker AK, Kem SE, Yeo CJ, Lillemoe KD, Cameron JL, Offerhaus GJ, Hicks JL, Wilentz RE, Goggins MG, De Marzo AM, Hruban RH, Maitra A:Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161:1541-1547, 2002.

• 3) Jan-Bart M Koorstra, Steven R Hustinx, G Johan A Offerhaus, Anirban Maitra:Pancreatic Carcinogenesis. Pancreatology 8:110-125, 2008.
  pubmed

• 4) Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE:Frequent somatic mutations and homozygous deletions of the p16 (MTS 1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994.

• 5) Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP:Structural basis forinibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-243, 1998.
  pubmed

• 6) Liggett WH Jr, Sidransky D:Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16:1197-1206, 1998.

• 7) Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B:14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3-11, 1997.

• 8) Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP:Molecular prognostic markers in pancreatic cancer:a systematic review. Eur J Cancer 41:2213-2236, 2005.
  pubmed

• 9) Almoguera C, Shibata D, Forrester K, Martin J, Amheim N, Perucho M:Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988.

• 10) Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH:Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 1; 67:9518-9527, 2007.

P.95 掲載の参考文献

• 1) Mok TS, Wu YL, Thong Prasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwakd Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M:Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 3;361 (10):947-957, 2009.
  pubmed

• 2) Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezenek I, Klingelschmitt G, Klugharnmer B, Giaccone G:Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre, randomised,, placebo-controlled phase 3 study. Lancet Oncol 11(6):521-529, 2010.

• 3) Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M:Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 20;23 (27):6674-6681, 2005.

• 4) Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B:Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer:results of a mult-center study. Eur J Cardiothorac Surg 25 (1):131-134, 2004.

• 5) Vansteenkiste J, Zielinski M, Linder A, et al:Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) [abstract 7554]. J Clin Oncol 25 (suppl 18):398s, 2007.

• 6) Gupta K, Cooper C:A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 9:137-145, 2008.

• 7) Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG:Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advancedstage non-small-cell lung cancer. J Clin Oncol 26:3979-3986, 2008.

• 8) Manegold C, Thatcher N, Benner RJ, et al:Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [abstract 8017]. J Clin Oncol 26 (suppl 15):428s, 2008.
  pubmed

• 9) Hirsh V, Boyer M, Rosell R, et al:Randomized phase HI trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [abstract 8016]. J Clin Oncol 26 (suppl 15):428s, 2008.

P.103 掲載の参考文献

• 1) Kelsey JL, Gammon MD, John EM:Reproductive factors and breast cancer. Epidemiol Rev 15 (1):36-47, 1993.
  pubmed

• 2) Rockhill B, Byme C, Rosner B, Louie MM, Colditz G:Breast cancer risk prediction with a log-incidence model:evaluation of accuracy. J Clin Epidemiol 56 (9):856-861, 2003.

• 3) Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL:Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 21;269 (15):1970-1974, 1993.
  pubmed

• 4) Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G:Identification of the breast cancer susceptibility gene BRCA2. Nature 21-28;378 (6559):789-792, 1995.

• 5) Dunn BK, Ford LG:Hormonal interventions to prevent hormonal cancers:breast and prostate cancers. Eur J Cancer Prev 16 (3):232-242, 2007.
  pubmed

• 6) Elston CW:Classification and grading of invasive breast carcinoma. Verh Dtsch Ges Pathol 89:35-44, 2005.
  pubmed

• 7) Hall JM, McDonnell DP:Coregulators in nuclear estrogen receptor action:from concept to therapeutic targeting. Mol Interv 5 (6):343-357, 2005.
  pubmed

• 8) Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ:Predictive markers of anthracycline benefit:a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11(3):266-274, 2010.

• 9) Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S:Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 1;25 (28):4405-4413, 2007.
  pubmed

• 10) Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, Pardee AB:Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappa B activation. Cancer Res 15;63 (2):290-295, 2003.

• 11) Nicolini A, Ferrari P, Cavazzana A, Carpi A, Berti P, Miccoli P:Conventional and new emerging prognostic factors in breast cancer:an update. Biomark Med 1 (4):525-540, 2007.
  pubmed

• 12) Ohta T, Fukuda M:Cell cycle regulators as prognostic factors of breast cancers. Nippon Rinsho 58 (Suppl):448-453, 2000.

• 13) Pegram MD, Pauletti G, Slamon DJ:HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52 (1-3):65-77, 1998.

• 14) Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L:Use of chemotherapy plus a monoclonal anti-body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.

• 15) Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D:Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006.
  pubmed

• 16) Shinichiro Akiyama, Hiroyasu Yasuda, Hiroyuki Abe:Anti-tumor effect of dendritic cell-based immunotherapy in the patients with advanced breast cancer. AACR 102ND ANNUAL MEETING (Abstract No. LB-154), Florida.

P.110 掲載の参考文献

• 1) Bansal N, Yendluri V, Wenham RM:The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16 (1):8-13, 2009.
  pubmed

• 2) Bokhman JV:Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 (1):10-17, 1983.
  pubmed

• 3) Lax SF:Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 39 (1):46-54, 2007.
  pubmed

• 4) Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X, Matias-Guiu X:Molecular pathology of endometrial carcinoma:practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 62 (9):777-785, 2009.
  pubmed

• 5) Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY:Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 23 ;6:21, 2006.

• 6) Liu FS:Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 46 (1):26-32, 2007.
  pubmed

• 7) SF Lax:Molecular genetic pathways in various types of endometrial carcinoma:from a phenotypical to a molecularbased classification. Virchows Arch 444 (3):213-223, 2004.

• 8) Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ:Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 1;26 (50):7158-7162, 2007.

• 9) Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM:Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68 (17):6902-6907, 2008.
  pubmed

• 10) Kim JJ, Goldie SJ:Health and economic implications of HPV vaccination in the United States. N Engl J Med 21;359 (8):821-832, 2008.
  pubmed

• 11) Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G;HPV PATRICIA Study Group, Greenacre M:Efficacy of human papilloma-virus (HPV)-16/18AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study in young women. Lancet 25;374 (9686):301-314, 2009.

P.119 掲載の参考文献

• 1) Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C:Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (4):451-458, 1976.
  pubmed

• 2) Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al.:A revised European:-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 1;84 (5):1361-1392, 1994

• 3) Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK:World Health Organization Classification of lymphomas:awork in progress. Ann Oncol 9 (Suppl 5):S25-30, 1998.

• 4) Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J:Lymphoma classification-from controversy to consensus:the R. E. A. L and WHO Classification of lymphoid neoplasms. Ann Oncol 11 (Suppl 1):3-10, 2000.

• 5) Swerdlow SH, Campo E, Harris NL, et al (eds):WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition, Lyon, IARC Press, 2008.

• 6) Tagawa H, Tsuzuki S, Suzuki R, Karnan S, Ota A, Kameoka Y, Suguro M, Matsuo K, Yamaguchi M, Okamoto M, Morig, hima Y, Nakamura S, Seto M:Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma:comparison between CD5-positive and CD5-negative cases. Cancer Res 1;64 (17):5948-5955, 2004.

• 7) Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, Morishima Y, Nakamura S, Seto M:Genome-wide array-based CGH for mantle cell lymphoma:identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 17;24 (8):1348-1358, 2005.
  pubmed

• 8) Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S, Seto M:Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 1;106 (5):1770-1777, 2005.
  pubmed

• 9) Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M:Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 1;107 (11):4500-4507, 2006.

• 10) Nakashima Y, Tagawa H, Suzuki R, Kaman S, Karube K, Ohshima K, Muta K, Nawata H, Morishima Y, Nakamura S, Seto M:Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia:different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/r-cell lymphoma, nasal type. Genes Chromosomes Cancer 44 (3):247-255, 2005.

• 11) Wong sw, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY, Lee CY, Quah SI, Fow C, Chung C, So I, Tan BS, Choo HL, Rosli R, Cheong SK, Leong CO:Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 5:2010 (Web Journal Report)

• 12) Di Nicolantonio F, Arena S, Tabemero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A:Deregulation of the P13K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2;120 (8):2858-2866, 2010.

• 13) Kremer M, Sliva K, Klemke CD, Schnierle BS:Cutaneous T-cell lymphoma cells are sensitive to rapamycin. Exp Dermatol 19 (9):800-805, 2010.

• 14) Huang S, Houghton PJ:Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3 (4):371-377, 2003.
  pubmed

• 15) Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P:Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 15;321 (5891):974-977, 2008.

• 16) Tan J, Cang S, Ma Y, Petrillo RL, Liu D:Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 4;3:5, 2010.

• 17) Czuczman MS, Gregory SA:The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 51 (6):983-994, 2010.

• 18) Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umafia P:Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 3;115 (22):4393-4402, 2010.

• 19) Wong BY, Dang NH:Ihlotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 10 (8):1251-1258, 2010.
  pubmed

P.125 掲載の参考文献

• 1) Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH:Immunotherapy of hormone-refractory prostate cancer with antigen-Loaded dendritic cells. J Clin Oncol 1;18:3894-3903, 2000.

P.128 掲載の参考文献

• 1) Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S, Ikeba A, Takahashi E, Sakaguchi N, Yokota A, Hosen N, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Aozasa K, Noguchi S, Sugiyama H:Overexpression of the Wilms:tumor gene WT-1 in primary thyroid cancer. Cancer Sci 94 (7):606-611, 2003.

• 2) Papewalis C, Ehlers M, Schott M:Advances in cellular therapy for the treatment of thyroid cancer. J Oncol 2010:179491, 2010.
  pubmed

P.131 掲載の参考文献

• 1) Shen P, Wanek LA, Morton DL:Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 7 (8):554-559, 2000.
  pubmed

• 2) Atkins MB, Kunkel L, Sznol M, Rosenberg SA:High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma:long-term survival update. Cancer J Sci Am 6 (Suppl-1):S11-14, 2000.

• 3) Wang TS, Lowe L, Smith JW 2nd, Francis IR, Sondak VK, Dworzanian L, Finkelstein S, Slingluff CL Jr, Johnson TM:Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg 2 (8):915-919, 1998.

• 4) Wagner JD, Gordon MS, Chuang TY, Coleman JJ 3rd:Current therapy of cutaneous melanoma. Plast Reconstr Surg 105 (5):1774-1799, 2000.
  pubmed

• 5) Feun L, Marini A, Moffat F, Savaraj N, Hurley J, Mazumder A:Cyclosporine A, alpha-Interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen:aphase II study in advanced melanoma. Cancer Invest 23 (1):3-8, 2005.

• 6) Atallah E, Flaherty L:Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6 (3):185-193, 2005.
  pubmed

• 7) Atkins MB:The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 9 (2):205-213, 1997.
  pubmed

• 8) Atkins MB, Kunel L, Sznol M, Rosenberg SA:High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma:long-term survival update. Cancer J Sci Am 6 (Suppl 1):S11-14, 2000.

• 9) Huncharek M, Caubet JF, McGarry R:Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma:a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11(1):75-81, 2001.
  pubmed

• 10) Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A:Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 19;187 (2):265-270, 1998.

• 11) Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A:Induction of primary NY-ESO-1 immunity:CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers. Proc Natl Acad Sci USA 24;97 (22):12198-12203, 2000.

• 12) Jager E, Jager D, Knuth A:Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106 (6):817-820, 2003.
  pubmed

• 13) Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E:Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 20;26 (36):5950-5956, 2008.
  pubmed

• 14) Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bemstein SH, Canniff PC, Shamla A, Gomez-Navarro J:Tremelimumab (CP-675, 206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12 (7):873-883, 2007.

• 15) Tarhini AA, Kirkwood JM:Tremeumumab (CP-675, 206):a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 8 (10):1583-1593, 2008.
  pubmed

• 16) Srivastava P:Interaction of heat shock proteins with peptides and antigen presenting cells:chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395-425, 2002.
  pubmed

• 17) Schadendorf D, Ugurel S, Schuler-Thumer B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kampgen E, Schuler G:DC study group of the DeCOG:Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 (4):563-570, 2006.